T-MAXIMUM Pharmaceutical
PrivateLast Round
Angel
Aug 19, 2021
Momentum
Top 50%
of companies Caplight tracks
Company Overview
T-MAXIMUM Pharmaceutical is a biotechnology company that develops allogeneic, off-the-shelf CAR-T cell therapies for the treatment of advanced solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
T-MAXIMUM Pharmaceutical Comparables
Compare T-MAXIMUM Pharmaceutical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tikva Allocell | 85% | |
| PersonGen BioTherapeutics | 78% | |
| BrainChild Bio, Inc. | 77% | |
T-MAXIMUM Pharmaceutical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Angel | Aug 19, 2021 |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 15, 2026
Grew 300% QoQ from 1 to 4 employees.
- Aug 19, 2021
Completed an Angel funding round.
T-MAXIMUM Pharmaceutical Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about T-MAXIMUM Pharmaceutical's valuation, stock price, and market status.